Pregnancy outcome after first trimester exposure to domperidone—An observational cohort study

• DOI: 10.1111/jog.14709
• Publication Date: 2021-02-26T00:00:10Z
• Authors: Kayoko Hishinuma; Ritsuko Yamane; Ikuko Yokoo; Takahide Arimoto; Kunihiko Takahashi; Mikako Goto; Yoshiyuki Saito; Ken Nakajima; Atsuko Murashima; Masahiro Hayashi
• Keywords: Domperidone; Third trimester

Abstract Aim To assess the teratogenic risk of domperidone by comparing incidence major malformation with to a control. Methods Pregnancy outcome data were obtained for women at two Japanese facilities that provide counseling on drug use during pregnancy between April 1988 and December 2017. The was calculated among infants born taking ( n = 519), nonteratogenic drugs (control, 1673), or metoclopramide (reference, 241) first trimester pregnancy. Using control group as reference, crude odds ratio (OR) in groups using univariable logistic regression analysis. Adjusted OR also multivariable analysis adjusted various other factors. Results 2.9% (14/485, 95% confidence interval [CI]: 1.6–4.8) group, 1.7% (27/1554, 95%CI: 1.1–2.5) 3.6% (8/224, 1.6–6.9) group. showed no significant difference (adjusted OR: 1.86 [95%CI: 0.73–4.70], p 0.191) 2.20 0.69–6.98], 0.183). Conclusions This observational cohort study exposure not associated increased infants. These results may help alleviate anxiety patients who took